Showing results (131-140 of 250) with videos related to

Sort By:
Pageof 25
European Journal of Cancer (Oxford, England : 1990)|January 18, 2022
Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlusVictoria Atkinson, Caroline Robert, Jean J Grob, et al.
Breast Cancer Research : BCR|November 14, 2012
The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trialHelena Linardou, Konstantine T Kalogeras, Ralf Kronenwett, et al.
Plos One|August 8, 2014
Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17Vassiliki Kotoula, Mattheos Bobos, Zoi Alexopoulou, et al.
Cancer Genomics & Proteomics|February 20, 2021
Androgen Receptor and PIM1 Expression in Tumor Tissue of Patients With Triple-negative Breast CancerAliki Ntzifa, Areti Strati, Georgia-Angeliki Koliou, et al.
Anticancer Research|August 6, 2005
Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II studyDimosthenis V Skarlos, Haralabos P Kalofonos, George Fountzilas, et al.
Plos One|February 9, 2013
Replication and predictive value of SNPs associated with melanoma and pigmentation traits in a Southern European case-control studyIrene Stefanaki, Orestis A Panagiotou, Elisavet Kodela, et al.
Melanoma Research|May 16, 2018
Epidemiological trends in the diagnosis of melanoma in a Southern European population: analysis of a large database from a tertiary referral centerDimosthenis Tsoutsos, Stefanos Papadopoulos, George Kehagias, et al.
Breast Cancer Research : BCR|April 20, 2010
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trialChristos Markopoulos, Evagelos Tzoracoleftherakis, Athanassios Polychronis, et al.
The New England Journal of Medicine|February 17, 2006
Prognostic significance of autoimmunity during treatment of melanoma with interferonHelen Gogas, John Ioannovich, Urania Dafni, et al.
Cancer Immunology Research|April 6, 2021
Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid TumorsMaria Grigoriou, Aggelos Banos, Aikaterini Hatzioannou, et al.
Pageof 25